Market News
Stay updated with the latest market trends, earnings, and economic indicators.
Anupam Rasayan becomes world's first to make ETFA using flow chemistry
Anupam Rasayan India Ltd has achieved a global first by commercialising Ethyl trifluoroacetate production using its unique continuous flow chemistry technology. This advanced method offers enhanced safety and efficiency over traditional batch processes. ETFA is a vital component for pharmaceuticals and life sciences.
Anupam Rasayan becomes first company to commercialise ETFA, eyes $500 million market
Anupam Rasayan said it will continue to invest in advanced process technologies, research capabilities and sustainable manufacturing practices as part of its long-term growth strategy.
Multibagger Anupam Rasayan stock to be in focus on Friday on ETFA manufacturing milestone
Anupam Rasayan India announces commercialization of ETFA production via a proprietary continuous flow chemistry platform, making it the first globally to do so. The market potential for ETFA is $500-600 million, crucial for fluorinated compounds in pharmaceuticals and life sciences.
CRISIL places Anupam Rasayan's credit ratings on watch
The ratings have been placed on watch following announcement by ARIL of acquisition of 43.3-48.2% equity stake in Bliss GVS Pharma, a pharmaceutical (pharma) formulations company based in India, which may be funded through debt, equity or internal accrual.
Here's why Bliss GVS Pharma shares have surged over 45% over the last 10 sessions
Bliss GVS Pharma shares have surged over 45% since the time it announced its deal with Anupam Rasayan. The WHO update is another positive news from the stock.
Anupam Rasayan India consolidated net profit declines 4.31% in the March 2026 quarter
Sales rise 27.12% to Rs 635.78 crore
Anupam Rasayan to acquire up to 43 pc stake in Bliss GVS Pharma for around Rs 1,369 cr
Specialty chemicals maker Anupam Rasayan India is set to acquire up to 43.3% of Bliss GVS Pharma for an estimated Rs 1,369.51 crore, with an open offer for an additional 26%. This strategic move aims to strengthen Anupam Rasayan's presence across the pharmaceutical value chain, from key starting materials to finished dosage formulations.
Anupam Rasayan enters formulations business with ₹1,369 cr Bliss GVS Pharma acquisition
Anupam Rasayan will acquire up to 74.2% stake in Bliss GVS Pharma, strengthening its presence across the pharmaceutical value chain and expanding its reach in regulated global markets.
Breakout stocks to buy or sell: Sumeet Bagadia recommends five shares to buy today — 11 March 2026
Breakout stocks to buy or sell: Sumeet Bagadia recommends five shares to buy today — Anupam Rasayan India, Schneider Electric Infrastructure, MM Forgings, Godawari Power and Ispat, and Aurobindo Pharma.
Anupam Rasayan completes USD150-mln acquisition of US speciality chemical maker Jayhawk
Anupam Rasayan India has acquired US-based Jayhawk Fine Chemicals Corporation for approximately USD 150 million. This strategic move aims to broaden Anupam Rasayan's global presence and access new end-use markets. The acquisition is expected to enhance its integrated platform and create cross-selling opportunities. Jayhawk's operations in performance materials will now be consolidated into Anupam Rasayan's financials.
Bliss GVS hits 20% upper circuit as Anupam Rasayan to acquire up to 43% stake for Rs 1,369 crore
Anupam Rasayan India Ltd reported a 40 percent rise in consolidated net profit at Rs 222.19 crore for 2025-26, compared with Rs 159.9 crore in the previous year.